2023-05-16 10:25:23 ET
- Amgen ( NASDAQ: AMGN ) is expected to mount a "very aggressive" defense if the Federal Trade Commission files a lawsuit to block the $28 billion acquisition of Horizon Therapeutics ( NASDAQ: HZNP ), according to CNBC.
- FTC commissioners have not yet met on the Horizon/Amgen deal and haven't voted, according to CNBC's David Faber, who cited sources familiar.
- Several media reports from Monday indicated that the FTC is preparing a lawsuit as soon as Tuesday to block the combination.
- Developing story ...
For further details see:
Amgen will mount a `very aggressive' defense if FTC sues to block Horizon